

I hereby certify that this correspondence is being hand-delivered to:
Examiner Teresa D. Wessendorf/ Examiner Andrew J. Wang
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202
703-308-3967

On: October 8, 2003

By: Meredith K. Meyer

Printed Name: Meredith K. Meyer

Attorney Docket No. 0155.130US
(formerly 18097-030310US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen et al.

Application No.: 09/724,869

Filed: November 28, 2000

For: OPTIMIZATION OF
IMMUNOMODULATORY
PROPERTIES OF GENETIC
VACCINES

Examiner: Teresa D. Wessendorf

Art Unit: 1639

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §§ 1.97
AND 1.98**

Examiner Teresa D. Wessendorf
Examiner Andrew J. Wang
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202

Dear Madam/Sir:

The references cited on attached form PTO/SB/08A-B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Application No. 09/724,869


Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

A Fee Transmittal Form is submitted concurrently herewith, authorizing the Commissioner to deduct any required fee from, or credit any overpayment to, the undersigned's Deposit Account No. 50-0990.

Respectfully submitted,

October 8, 2003

By: 
R. Danny Huntington
Registration No. 27,903
Sharon E. Crane
Registration No. 36,113
Mercedes K. Meyer
Registration No. 44,939
Attorneys for Applicants

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560



I hereby certify that this correspondence is being hand-delivered to:
Examiner Teresa D. Wessendorf/ Examiner Andrew J. Wang
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202
703-308-3967

On: October 8 2003

By: Mercedes K. Meyer

Printed Name: Mercedes K. Meyer

Attorney Docket No. 0155.130US
(formerly 18097-030310US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen et al.

Application No.: 09/724,869

Filed: November 28, 2000

For: OPTIMIZATION OF
IMMUNOMODULATORY
PROPERTIES OF GENETIC
VACCINES

Examiner: Teresa D. Wessendorf

Art Unit: 1639

**THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §§ 1.97
AND 1.98**

Examiner Teresa D. Wessendorf
Examiner Andrew J. Wang
United States Patent and Trademark Office
Art Unit 1639
1911 S. Clark Place
Crystal Mall One, 7th Floor
Arlington, VA 22202

Dear Madam/Sir:

The three references cited on attached form PTO/SB/08A-B are being called to the attention of the Examiner. Although these three references are not mentioned in the "Request by Applicants for Interference Pursuant to 37 C.F.R. § 1.607" submitted concurrently herewith, Applicants respectfully request that the cited information be expressly considered during the prosecution of this application and these references be made of record therein and appear among the "references cited" on any patent to issue therefrom. Copies of these three references are enclosed.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	6,376,246		Cramer et al.	04-09-2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
	2	WO	91/19818	A1	Affymax Technologies N.V.	12-26-1991	
	3	WO	92/01047	A1	Cambridge Antibody Technology Limited	01-23-1992	
	4	WO	92/18619	A1	The Scripps Research Institute	10-29-1992	
	5	WO	94/01567	A1	Unilever PLC	01-20-1994	
	6	WO	94/18330	A1	Unilever PLC	08-18-1994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	7	Aggarwal & Gutterman eds., HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH, Vol. II (1996) (Table of Contents for Vols. 1 & II)	
	8	Alcami et al., "A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection," <i>Cell</i> 71(1):153-67 (1992)	
	9	Apostolopoulos et al., "Breast cancer immunotherapy: Current status and future prospects," <i>Immunol. and Cell. Biol.</i> 74:457-64 (1996)	
	10	Atamas et al., "An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation," <i>J. Immunol.</i> 156(2):435-41 (1996)	
	11	Aversa et al., "SLAM and its role in T cell activation and Th cell responses," <i>Immunol. Cell Biol.</i> 75(2):202-5 (1997)	
	12	Bach et al., "The IFN gamma receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> 15:563-91 (1997)	
	13	Baggiolini et al., "Human Cytokines: An Update," <i>Annu. Rev. Immunol.</i> 15:675-705 (1997)	
	14	Balbas et al., "Design and Construction of Expression Plasmid Vectors in Escherichia coli," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:14-37 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
	15	Basham et al., "Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action," <i>J. Immunol.</i> 141(8):2855-60 (1988)	
	16	Beck et al., "Analysis of Multiple Plasmodium falciparum Infections in Tanzanian Children during the Phase II Trial of Malaria Vaccine SPf66," <i>J. Inf. Disease</i> 175:921-26 (1997)	

17	Becket <i>et al.</i> , "Characterization of a Prostate Carcinoma Mucin-Like Antigen (PMA)," <i>Int. J. Cancer</i> 62:703-10 (1995)	
18	Bramson <i>et al.</i> , "Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12," <i>Hum. Gene Ther.</i> 7(3):333-42 (1996)	
19	Brusselle <i>et al.</i> , "Role of IFN- γ in the Inhibition of Allergic Airway Inflammation Caused by IL-12," <i>Am. J. Respir. Cell Mol. Biol.</i> 17:767-71 (1997)	
20	Censini <i>et al.</i> , "cag, a pathogenicity island of <i>Helicobacter pylori</i> , encodes type I-specific and disease-associated virulence factors," <i>PNAS USA</i> 93:14648-53 (1996)	
21	Chen <i>et al.</i> , "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library," <i>PNAS USA</i> 93(5):1997-2001 (1996)	
22	Chow <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> 71(1):169-78 (1997)	
23	Ciernik <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with DNA Vaccines Expressing Single T Cell Epitopes," <i>J. Immunol.</i> 156:2369-75 (1996)	
24	Cohen <i>et al.</i> , "Host factors in the pathogenesis of HIV disease," <i>Immunol. Rev.</i> 159:31-48 (1997)	
25	Cortese <i>et al.</i> , "Selection of biologically active peptides by phage display of random peptide libraries," <i>Curr. Opin. Biotechnol.</i> 7(6):616-21 (1996)	
26	Curtis <i>et al.</i> , "Recombinant Soluble Interleukin-11 (IL-11) Receptor alpha Chain Can Act as an IL-11 Antagonist," <i>Blood</i> 90(11):4403-12 (1997)	
27	Cwirla <i>et al.</i> , "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <i>Science</i> 276:1696-9 (1997)	
28	Dagan <i>et al.</i> , "High level expression and production of recombinant human interleukin analogs," <i>Protein Expr. Purif.</i> 3(4):290-4 (1992)	
29	Devos <i>et al.</i> , "Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease," <i>J. Leukoc. Biol.</i> 57(6):813-19 (1995)	
30	De Vries <i>et al.</i> , "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," <i>J. Invest. Dermatol.</i> 102(2):141-4 (1994)	
31	De Vries <i>et al.</i> , <i>Interleukin-4 and Interleukin-13</i> , Chap. 8, in <i>CYTOKINE REGULATION OF HUMORAL IMMUNITY: BASIC AND CLINICAL ASPECTS</i> 195-215 (C. M. Snapper, West Sussex, UK, John Wiley and Sons, 1996)	
32	De Vries <i>et al.</i> , "Modulation of the human IgE response," <i>Eur. Respir. J. Suppl.</i> 22:58s-62s (1996)	
33	De Waal Malefyt <i>et al.</i> , "A Novel Cytokine Belonging to the IL-10 Gene Family Affects Human Monocytes and T Cells," Abstract, 13th European Immunology Meeting, Amsterdam, Netherlands, June 1997, <i>Immunol. Letters</i> 56(1):211 (May 1997)	
34	Donnelly <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-48 (1997)	
35	Dudler <i>et al.</i> , "A Link Between Catalytic Activity, IgE-Independent Mast Cell Activation and Allergenicity of Bee Venom Phospholipase A ₂ ," <i>J. Immunol.</i> 155(5):2605-13 (1995)	
36	Eckhart <i>et al.</i> , "Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus," <i>J. Gen. Virol.</i> 77 (9):2001-8 (1996)	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

37	Fomsgaard <i>et al.</i> , "Improved humoral and cellular immune response against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted in the hepatitis B surface antigen," <i>Scand. J. Immunol.</i> 47(4):289-95 (1998)	
38	Foy <i>et al.</i> , "Immune regulation by CD40 and its ligand GP39," <i>Annu. Rev. Immunol.</i> 14:591-617 (1996)	
39	Fromm <i>et al.</i> , "Expression of genes transferred into monocot and dicot plant cells by electroporation," <i>PNAS USA</i> 82(17):5824-28 (1985)	
40	Gauchat <i>et al.</i> , "Regulation of human IgE synthesis: the role of CD4+ and CD8+ T-cells and the inhibitory effects of interferon-alpha," <i>Eur. Respir. J. Suppl.</i> 13:31s-38s (1991)	
41	Goff <i>et al.</i> , "Laboratory Methods: Efficient Saturation Mutagenesis of a Pentapeptide Coding Sequence Using Mixed Oligonucleotides," <i>DNA</i> 6(4):381-388 (1987)	
42	Greenfeder <i>et al.</i> , "Insertion of a Structural Domain of Interleukin (IL)-1B Confers Agonist Activity to the IL-1 Receptor Antagonist," <i>J. Biol. Chem.</i> 270:22460-6 (1995)	
43	Grewal <i>et al.</i> , "The CD40-CD154 system in anti-infective host defense," <i>Curr. Opin. Immunol.</i> 9(4):491-7 (1997)	
44	Grunig <i>et al.</i> , "Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis," <i>J. Exp. Med.</i> 185(6):1089-99 (1997)	
45	Hannum <i>et al.</i> , "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," <i>Nature</i> 343:336-40 (1990)	
46	Hathcock <i>et al.</i> , "Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function," <i>J. Exptl. Med.</i> 180:631-40 (1994)	
47	Herz <i>et al.</i> , "Molecular approaches to receptors as targets for drug discovery," <i>J. Recept. Signal Transduct. Res.</i> 17(5):671-776 (1997)	
48	Herzenberg <i>et al.</i> eds., WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY (5 th ed. 1996) (index and first pages of Chaps. 220, 226, 227)	
49	Hess <i>et al.</i> , "Superior efficacy of secreted over somatic antigen display in recombinant <i>Salmonella</i> vaccine induced protection against listeriosis," <i>PNAS</i> 93:1458-63 (1996)	
50	Hill <i>et al.</i> , "Mutagenesis with Degenerate Oligonucleotides: An Efficient Method for Saturating a Defined DNA Region with Base Pair Substitutions," in <i>METHODS IN ENZYMOLOGY: RECOMBINANT DNA</i> 155:558-568 (Ray Wu ed., Acad. Press, Inc., 1987)	
51	Horuk, "Molecular properties of the chemokine receptor family," <i>TIPS</i> 15:159-165 (1994)	
52	Horwitz <i>et al.</i> , "Saturation Mutagenesis Using Mixed Oligonucleotides and M13 Templates Containing Uracil," in <i>METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY</i> 185:599-611 (David V. Goeddel ed., Acad. Press, Inc. 1990)	
53	Ihle <i>et al.</i> , "Signaling through the hematopoietic cytokine receptors," <i>Annu. Rev. Immunol.</i> 13:369-98 (1995)	
54	Kaufman, "Vectors Used for Expression in Mammalian Cells," in <i>METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY</i> 185:487-511 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
55	Kay <i>et al.</i> eds., PHAGE DISPLAY OF PEPTIDES AND PROTEINS: A LABORATORY MANUAL (Acad. Press, Inc., 1996) (first page of Chap. 5)	
56	Krieger <i>et al.</i> , "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)," <i>Annu. Rev. Biochem.</i> 63:601-	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	37 (1994)	
57	Kroemer <i>et al.</i> , "Immunoregulation by cytokines," <i>Crit. Rev. Immunol.</i> 13(2):163-91 (1993)	
58	Laberge <i>et al.</i> , "Secretion of IL-16 (Lymphocyte Chemoattractant Factor) from Serotonin-Stimulated CD8 ⁺ T Cells In Vivo," <i>J. Immunol.</i> 156(1):310-5 (1996)	
59	Le Borgne <i>et al.</i> , "In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen," <i>Virology</i> 240:304-15 (1998)	
60	Le Grice, "Regulated Promoter for High-Level Expression of Heterologous Genes for <i>Bacillus subtilis</i> ," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:201-15 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
61	Levinson, "Expression of Heterologous Genes in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:485-87 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
62	Livnah <i>et al.</i> , "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8," <i>Science</i> 273:464-71 (1996)	
63	Ma <i>et al.</i> , "Antibody production and engineering in plants," <i>Ann. NY Acad. Sci.</i> 792:72-81 (1996)	
64	Mattion <i>et al.</i> , "Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D," <i>J. Virol.</i> 69:5132-37 (1995)	
65	McLafferty <i>et al.</i> , "M13 bacteriophage displaying disulfide-constrained microproteins," <i>Gene</i> 128(1):29-36 (1993)	
66	Miele, "Plants as bioreactors for biopharmaceuticals: regulatory considerations," <i>Trends Biotechnol.</i> 15(2):45-50 (1997)	
67	Mosmann <i>et al.</i> , "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T cells," <i>Adv. Immunol.</i> 46:111-147 (1989)	
68	Murray <i>et al.</i> , "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allorecognition," <i>PNAS USA</i> 85:3535-39 (1988)	
69	Noguchi <i>et al.</i> , "IgE responsiveness to <i>Dermatophagoides farinae</i> in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2," <i>Int. Arch. Allergy Immunol.</i> 110(4):380-7 (1996)	
70	Ostermeier <i>et al.</i> , "A combinatorial approach to hybrid enzymes independent of DNA homology," <i>Nature</i> 391:1205-09 (1999)	
71	Ostermeier <i>et al.</i> , "Combinatorial protein engineering by incremental truncation," <i>PNAS USA</i> 96:3562-67 (1999)	
72	Parronchi <i>et al.</i> , "IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones," <i>J. Immunol.</i> 149(9):2977-83 (1992)	
73	Paul, <i>The Immune System: An Introduction</i> , Chap. 1, pp. 1-20 in FUNDAMENTAL IMMUNOLOGY (W. E. Paul, New York, Raven Press, 1993)	
74	Porcelli, "The CD1 family: a third lineage of antigen-presenting molecules," <i>Adv. Immunol.</i> 59:1-98 (1995)	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

75	Pumpens <i>et al.</i> , "Hepatitis B virus core particles as epitope carriers," <i>Intervirology</i> 38(1-2):63-74 (1995)
76	Quarantino <i>et al.</i> , "Similar antigenic surfaces, rather than sequence homology dictate T-cell epitope molecular mimicry," <i>PNAS USA</i> 92:10398-402 (1995)
77	Randhawa <i>et al.</i> , "In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha," <i>In Vitro Cell Dev. Biol. Anim.</i> 33(10):803-08 (1997)
78	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. I, pp. 1.53-1.59
79	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. II, pp. 15.51-15.113
80	Schrijver <i>et al.</i> , "Comparison of DNA application methods to reduce BRSV shedding in cattle," <i>Vaccine</i> 16(2-3):130-4 (1998)
81	Simmons <i>et al.</i> , "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," <i>Science</i> 276:276-9 (1997)
82	Stern <i>et al.</i> , Chap. 4, <i>Interleukin-12</i> , in HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH 74-96 (Aggarwal & Guterman eds., 1996)
83	Tan <i>et al.</i> , "Characterization of IL-10 Receptors on Human and Mouse Cells," <i>J. Biol. Chem.</i> 268(28):21053-59 (1993)
84	Thomas <i>et al.</i> , "Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>PNAS USA</i> 92:3779-83 (1995)
85	Tuite, "Strategies for the genetic manipulation of <i>Saccharomyces cerevisiae</i> ," <i>Crit. Rev. Biotechnol.</i> 12(1-2):157-88 (1992)
86	Udagawa <i>et al.</i> , "Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation," <i>J. Exp. Med.</i> 185(6):1005-12 (1997)
87	Ulrich <i>et al.</i> , "Chimeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model," <i>Vaccine</i> 16(2-3):272-80 (1998)
88	Villbrandt <i>et al.</i> , "Investigations of the thermostability and function of truncated <i>Thermus aquaticus</i> DNA polymerase fragments," <i>Protein Eng'g</i> 10(11):1281-88 (1997)
89	Weiner <i>et al.</i> , "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS USA</i> 94:10833-7 (1997)
90	Yao <i>et al.</i> , "Human IL-17: A Novel Cytokine Derived from T Cells," <i>J. Immunol.</i> 155(12):5483-86 (1995)
91	York <i>et al.</i> , "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-96 (1996)
92	Yoshie <i>et al.</i> , "Novel lymphocyte-specific CC chemokines and their receptors," <i>J. Leukocyte Biol.</i> 62(5):634-44 (1997)
93	Zaremba <i>et al.</i> , "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen," <i>Cancer Res.</i> 57(20):4570-77 (1997)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 14 2007

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 This document is for use through 07/31/2006. OMB 0651-0032
 This document is for use through 07/31/2006. OMB 0651-0032
 This document is for use through 07/31/2006. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no person is required to provide information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00

Complete if Known

Application Number	09/724,869
Filing Date	November 28, 2000
First Named Inventor	Juha Punnonen
Examiner Name	Teresa Wessendorf
Art Unit	1639
Attorney Docket No	0155.130US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit AccountDeposit
Account
Number
Deposit
Account
Name

50-0990

Maxygen, Inc.

The Director is authorized to (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entry Fee Code (\$)	Small Entry Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$ 000

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
XX -20** = XX	XX	000	000
XX -3** = XX	XX	000	000
Multiple Dependent		000	000

Large Entry Fee Code (\$)	Small Entry Fee Code (\$)	Fee Description	Fee Paid
202 18	2202 9	Claims in excess of 20	
201 86	2201 43	Independent claims in excess of 3	
203 250	2203 145	Multiple dependent claim, if not paid	
204 86	2204 43	Reissue independent claims over original patent	
205 18	2205 9	Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$ 0000

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entry Fee Code (\$)	Small Entry Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 190	2053 130	Non-English specification	
1812 2,520	2812 2,520	For filing a request for ex parte reexamination	
1804 920	2804 920	Requesting publication of SIR prior to Examiner action	
1805 1,840	2805 1,840	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	2451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	2460 130	Petitions to the Commissioner	
1807 50	2807 50	Processing fee under 37 CFR 1.17(g)	
1806 180	2806 180	Submission of Information Disclosure Stmt	180.00
8021 40	28021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	2802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00

SUBMITTED BY

Name (Print Type) Margaret A. Powers

Registration No.
(Attorney/Agent)

39,804

Telephone (650) 298-5809

Signature

Date

10-07-03

Certificate of Mailing under 37 C.F.R. §1.8

I hereby certify that this is being hand delivered in an envelope addressed to Examiner Teresa Wessendorf, United States Patent and Trademark Office, Art Unit 1639, 1911 S. Clark Place, Crystal Mall One, 7th Floor, Arlington VA 22202: October 8 2003 on this date:

Typed or Printed Name: Mercedes K. MeyerDate: 10/8/03Signature: Mercedes K. Meyer

Application No. 09/724,869

Page 2


representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

A Fee Transmittal Form is submitted concurrently herewith, authorizing the Commissioner to deduct any required fee from, or credit any overpayment to, the undersigned's Deposit Account No. 50-0990.

Respectfully submitted,

October 8, 2003

By:



R. Danny Huntington

Registration No. 27,903

Sharon E. Crane


Registration No. 36,113

Mercedes K. Meyer

Registration No. 44,939

Attorneys for Applicants

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560



(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	6,368,861		Crameri et al.	04-23-2002	
	2	6,406,855		Patten et al.	06-18-2002	
	3	6,613,514		Patten et al.	09-02-2003	

FOREIGN PATENT DOCUMENTS								
Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	09/724,869
	Filing Date	November 28, 2000
	First Named Inventor	Juha Punnonen
	Group Art Unit	1639
	Examiner Name	Teresa Wessendorf
	Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	6,368,861		Crameri et al.	04-23-2002	
	2	6,406,855		Patten et al.	06-18-2002	
	3	6,613,514		Patten et al.	09-02-2003	

FOREIGN PATENT DOCUMENTS								
Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office	Number	Kind Code (if known)				

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/724,869
Filing Date	November 28, 2000
First Named Inventor	Juha Punnonen
Group Art Unit	1639
Examiner Name	Teresa Wessendorf
Attorney Docket Number	0155.130US

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	6,376,246		Crameri et al.	04-09-2002	

FOREIGN PATENT DOCUMENTS

Exami ner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number	Kind Code (if known)			
	2	WO	91/19818	A1	Affymax Technologies N.V.	12-26-1991	
	3	WO	92/01047	A1	Cambridge Antibody Technology Limited	01-23-1992	
	4	WO	92/18619	A1	The Scripps Research Institute	10-29-1992	
	5	WO	94/01567	A1	Unilever PLC	01-20-1994	
	6	WO	94/18330	A1	Unilever PLC	08-18-1994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exami ner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	7	Aggarwal & Gutterman eds., HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH, Vol. II (1996) (Table of Contents for Vols. 1 & II)
	8	Alcami <i>et al.</i> , "A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection," <i>Cell</i> 71(1):153-67 (1992)
	9	Apostolopoulos <i>et al.</i> , "Breast cancer immunotherapy: Current status and future prospects," <i>Immunol. and Cell. Biol.</i> 74:457-64 (1996)
	10	Atamas <i>et al.</i> , "An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation," <i>J. Immunol.</i> 156(2):435-41 (1996)
	11	Aversa <i>et al.</i> , "SLAM and its role in T cell activation and Th cell responses." <i>Immunol. Cell Biol.</i> 75(2):202-5 (1997)
	12	Bach <i>et al.</i> , "The IFN gamma receptor: a paradigm for cytokine receptor signaling," <i>Annu. Rev. Immunol.</i> 15:563-91 (1997)
	13	Baggiolini <i>et al.</i> , "Human Cytokines: An Update," <i>Annu. Rev. Immunol.</i> 15:675-705 (1997)
	14	Balbas <i>et al.</i> , "Design and Construction of Expression Plasmid Vectors in Escherichia coli," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:14-37 (David V. Goeddel ed., Acad. Press, Inc., 1990)
	15	Basham <i>et al.</i> , "Synergistic antitumor activity with IFN and monoclonal anti-idiotypic for murine B cell lymphoma. Mechanism of action," <i>J. Immunol.</i> 141(8):2855-60 (1988)
	16	Beck <i>et al.</i> , "Analysis of Multiple Plasmodium falciparum Infections in Tanzanian Children during the Phase II Trial of Malaria Vaccine SPf66," <i>J. Inf. Disease</i> 175:921-26 (1997)

17	Becket <i>et al.</i> , "Characterization of a Prostate Carcinoma Mucin-Like Antigen (PMA)," <i>Int. J. Cancer</i> 62:703-10 (1995)	
18	Bramson <i>et al.</i> , "Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12," <i>Hum. Gene Ther.</i> 7(3):333-42 (1996)	
19	Brusselle <i>et al.</i> , "Role of IFN- γ in the Inhibition of Allergic Airway Inflammation Caused by IL-12," <i>Am. J. Respir. Cell Mol. Biol.</i> 17:767-71 (1997)	
20	Censini <i>et al.</i> , "cag, a pathogenicity island of <i>Helicobacter pylori</i> , encodes type I-specific and disease-associated virulence factors," <i>PNAS</i> 93:14648-53 (1996)	
21	Chen <i>et al.</i> , "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library," <i>PNAS USA</i> 93(5):1997-2001 (1996)	
22	Chow <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> 71(1):169-78 (1997)	
23	Ciernik <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with DNA Vaccines Expressing Single T Cell Epitopes," <i>J. Immunol.</i> 156:2369-75 (1996)	
24	Cohen <i>et al.</i> , "Host factors in the pathogenesis of HIV disease," <i>Immunol. Rev.</i> 159:31-48 (1997)	
25	Cortese <i>et al.</i> , "Selection of biologically active peptides by phage display of random peptide libraries," <i>Curr. Opin. Biotechnol.</i> 7(6):616-21 (1996)	
26	Curtis <i>et al.</i> , "Recombinant Soluble Interleukin-11 (IL-11) Receptor alpha Chain Can Act as an IL-11 Antagonist," <i>Blood</i> 90(11):4403-12 (1997)	
27	Cwirla <i>et al.</i> , "Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine," <i>Science</i> 276:1696-9 (1997)	
28	Dagan <i>et al.</i> , "High level expression and production of recombinant human interleukin analogs," <i>Protein Expr. Purif.</i> 3(4):290-4 (1992)	
29	Devos <i>et al.</i> , "Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease," <i>J. Leukoc. Biol.</i> 57(6):813-19 (1995)	
30	De Vries <i>et al.</i> , "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," <i>J. Invest. Dermatol.</i> 102(2):141-4 (1994)	
31	De Vries <i>et al.</i> , <i>Interleukin-4 and Interleukin-13</i> , Chap. 8, in <i>CYTOKINE REGULATION OF HUMORAL IMMUNITY: BASIC AND CLINICAL ASPECTS</i> 195-215 (C. M. Snapper, West Sussex, UK, John Wiley and Sons, 1996)	
32	De Vries <i>et al.</i> , "Modulation of the human IgE response," <i>Eur. Respir. J. Suppl.</i> 22:58s-62s (1996)	
33	De Waal Malefyt <i>et al.</i> , "A Novel Cytokine Belonging to the IL-10 Gene Family Affects Human Monocytes and T Cells," Abstract, 13th European Immunology Meeting, Amsterdam, Netherlands, June 1997, <i>Immunol. Letters</i> 56(1):211 (May 1997)	
34	Donnelly <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-48 (1997)	
35	Dudler <i>et al.</i> , "A Link Between Catalytic Activity, IgE-Independent Mast Cell Activation and Allergenicity of Bee Venom Phospholipase A ₂ ," <i>J. Immunol.</i> 155(5):2605-13 (1995)	
36	Eckhart <i>et al.</i> , "Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus," <i>J. Gen. Virol.</i> 77 (9):2001-8 (1996)	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

37	Fomsgaard <i>et al.</i> , "Improved humoral and cellular immune response against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted in the hepatitis B surface antigen," <i>Scand. J. Immunol.</i> 47(4):289-95 (1998)	
38	Foy <i>et al.</i> , "Immune regulation by CD40 and its ligand GP39," <i>Annu. Rev. Immunol.</i> 14:591-617 (1996)	
39	Fromm <i>et al.</i> , "Expression of genes transferred into monocot and dicot plant cells by electroporation," <i>PNAS USA</i> 82(17):5824-28 (1985)	
40	Gauchat <i>et al.</i> , "Regulation of human IgE synthesis: the role of CD4+ and CD8+ T-cells and the inhibitory effects of interferon-alpha," <i>Eur. Respir. J. Suppl.</i> 13:31s-38s (1991)	
41	Goff <i>et al.</i> , "Laboratory Methods: Efficient Saturation Mutagenesis of a Pentapeptide Coding Sequence Using Mixed Oligonucleotides," <i>DNA</i> 6(4):381-388 (1987)	
42	Greenfeder <i>et al.</i> , "Insertion of a Structural Domain of Interleukin (IL)-1B Confers Agonist Activity to the IL-1 Receptor Antagonist," <i>J. Biol. Chem.</i> 270:22460-6 (1995)	
43	Grewal <i>et al.</i> , "The CD40-CD154 system in anti-infective host defense," <i>Curr. Opin. Immunol.</i> 9(4):491-7 (1997)	
44	Grunig <i>et al.</i> , "Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis," <i>J. Exp. Med.</i> 185(6):1089-99 (1997)	
45	Hannum <i>et al.</i> , "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor," <i>Nature</i> 343:336-40 (1990)	
46	Hathcock <i>et al.</i> , "Comparative Analysis of B7-1 and B7-2 Costimulatory Ligands: Expression and Function," <i>J. Exptl. Med.</i> 180:631-40 (1994)	
47	Herz <i>et al.</i> , "Molecular approaches to receptors as targets for drug discovery," <i>J. Recept. Signal Transduct. Res.</i> 17(5):671-776 (1997)	
48	Herzenberg <i>et al.</i> eds., WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY (5 th ed. 1996) (index and first pages of Chaps. 220, 226, 227)	
49	Hess <i>et al.</i> , "Superior efficacy of secreted over somatic antigen display in recombinant <i>Salmonella</i> vaccine induced protection against listeriosis," <i>PNAS</i> 93:1458-63 (1996)	
50	Hill <i>et al.</i> , "Mutagenesis with Degenerate Oligonucleotides: An Efficient Method for Saturating a Defined DNA Region with Base Pair Substitutions," in METHODS IN ENZYMOLOGY: RECOMBINANT DNA 155:558-568 (Ray Wu ed., Acad. Press, Inc., 1987)	
51	Horuk, "Molecular properties of the chemokine receptor family," <i>TIPS</i> 15:159-165 (1994)	
52	Horwitz <i>et al.</i> , "Saturation Mutagenesis Using Mixed Oligonucleotides and M13 Templates Containing Uracil," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:599-611 (David V. Goeddel ed., Acad. Press, Inc. 1990)	
53	Ihle <i>et al.</i> , "Signaling through the hematopoietic cytokine receptors," <i>Annu. Rev. Immunol.</i> 13:369-98 (1995)	
54	Kaufman, "Vectors Used for Expression in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:487-511 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
55	Kay <i>et al.</i> , eds., PHAGE DISPLAY OF PEPTIDES AND PROTEINS: A LABORATORY MANUAL (Acad. Press, Inc., 1996) (first page of Chap. 5)	
56	Krieger <i>et al.</i> , "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)," <i>Annu. Rev. Biochem.</i> 63:601-	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	37 (1994)	
57	Kroemer <i>et al.</i> , "Immunoregulation by cytokines," <i>Crit. Rev. Immunol.</i> 13(2):163-91 (1993)	
58	Laberge <i>et al.</i> , "Secretion of IL-16 (Lymphocyte Chemoattractant Factor) from Serotonin-Stimulated CD8 ⁺ T Cells In Vivo," <i>J. Immunol.</i> 156(1):310-5 (1996)	
59	Le Borgne <i>et al.</i> , "In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen," <i>Virology</i> 240:304-15 (1998)	
60	Le Grice, "Regulated Promoter for High-Level Expression of Heterologous Genes for <i>Bacillus subtilis</i> ," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:201-15 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
61	Levinson, "Expression of Heterologous Genes in Mammalian Cells," in METHODS IN ENZYMOLOGY: GENE EXPRESSION TECHNOLOGY 185:485-87 (David V. Goeddel ed., Acad. Press, Inc., 1990)	
62	Livnah <i>et al.</i> , "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8," <i>Science</i> 273:464-71 (1996)	
63	Ma <i>et al.</i> , "Antibody production and engineering in plants," <i>Ann. NY Acad. Sci.</i> 792:72-81 (1996)	
64	Mattion <i>et al.</i> , "Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D," <i>J. Virol.</i> 69:5132-37 (1995)	
65	McLafferty <i>et al.</i> , "M13 bacteriophage displaying disulfide-constrained microproteins," <i>Gene</i> 128(1):29-36 (1993)	
66	Miele, "Plants as bioreactors for biopharmaceuticals: regulatory considerations," <i>Trends Biotechnol.</i> 15(2):45-50 (1997)	
67	Mosmann <i>et al.</i> , "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T cells," <i>Adv. Immunol.</i> 46:111-147 (1989)	
68	Murray <i>et al.</i> , "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allorecognition," <i>PNAS USA</i> 85:3535-39 (1988)	
69	Noguchi <i>et al.</i> , "IgE responsiveness to <i>Dermatophagoides farinae</i> in young asthmatic children: IgE binding study using recombinant allergens of Der f1, Der f2 and mutant proteins of Der f2," <i>Int. Arch. Allergy Immunol.</i> 110(4):380-7 (1996)	
70	Ostermeier <i>et al.</i> , "A combinatorial approach to hybrid enzymes independent of DNA homology," <i>Nature</i> 19:1205-09 (1999)	
71	Ostermeier <i>et al.</i> , "Combinatorial protein engineering by incremental truncation," <i>PNAS USA</i> 96:3562-67 (1999)	
72	Parronchi <i>et al.</i> , "IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones," <i>J. Immunol.</i> 149(9):2977-83 (1992)	
73	Paul, <i>The Immune System: An Introduction</i> , Chap. 1, pp. 1-20 in FUNDAMENTAL IMMUNOLOGY (W. E. Paul. New York, Raven Press, 1993)	
74	Porcelli, "The CD1 family: a third lineage of antigen-presenting molecules," <i>Adv. Immunol.</i> 59:1-98 (1995)	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

75	Pumpens <i>et al.</i> , "Hepatitis B virus core particles as epitope carriers," <i>Intervirology</i> 38(1-2):63-74 (1995)
76	Quarantino <i>et al.</i> , "Similar antigenic surfaces, rather than sequence homology dictate T-cell epitope molecular mimicry," <i>PNAS USA</i> 92:10398-402 (1995)
77	Randhawa <i>et al.</i> , "In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha," <i>In Vitro Cell Dev. Biol. Anim.</i> 33(10):803-08 (1997)
78	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. I, pp. 1.53-1.59
79	Sambrook <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press, New York (2d ed. 1989), Vol. II, pp. 15.51-15.113
80	Schrijver <i>et al.</i> , "Comparison of DNA application methods to reduce BRSV shedding in cattle," <i>Vaccine</i> 16(2-3):130-4 (1998)
81	Simmons <i>et al.</i> , "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," <i>Science</i> 276:276-9 (1997)
82	Stern <i>et al.</i> , Chap. 4, <i>Interleukin-12</i> , in HUMAN CYTOKINES: HANDBOOK FOR BASIC AND CLINICAL RESEARCH 74-96 (Aggarwal & Gutterman eds., 1996)
83	Tan <i>et al.</i> , "Characterization of IL-10 Receptors on Human and Mouse Cells," <i>J. Biol. Chem.</i> 268(28):21053-59 (1993)
84	Thomas <i>et al.</i> , "Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3," <i>PNAS USA</i> 92:3779-83 (1995)
85	Tuite, "Strategies for the genetic manipulation of <i>Saccharomyces cerevisiae</i> ," <i>Crit. Rev. Biotechnol.</i> 12(1-2):157-88 (1992)
86	Udagawa <i>et al.</i> , "Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation," <i>J. Exp. Med.</i> 185(6):1005-12 (1997)
87	Ulrich <i>et al.</i> , "Chimeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model," <i>Vaccine</i> 16(2-3):272-80 (1998)
88	Villbrandt <i>et al.</i> , "Investigations of the thermostability and function of truncated <i>Thermus aquaticus</i> DNA polymerase fragments," <i>Protein Eng'g</i> 10(11):1281-88 (1997)
89	Weiner <i>et al.</i> , "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>PNAS USA</i> 94:10833-7 (1997)
90	Yao <i>et al.</i> , "Human IL-17: A Novel Cytokine Derived from T Cells," <i>J. Immunol.</i> 155(12):5483-86 (1995)
91	York <i>et al.</i> , "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-96 (1996)
92	Yoshie <i>et al.</i> , "Novel lymphocyte-specific CC chemokines and their receptors," <i>J. Leukocyte Biol.</i> 62(5):634-44 (1997)
93	Zaremba <i>et al.</i> , "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen," <i>Cancer Res.</i> 57(20):4570-77 (1997)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.